Veracyte, Inc.

Veracyte’s molecular diagnostic tests are widely used in clinical practice for the diagnosis and management of various cancers. Their products have demonstrated high performance in resolving diagnostic ambiguity for thyroid nodules, prostate/breast/bladder/kidney cancers, interstitial lung diseases, diffuse large B-cell lymphoma, and early-stage lung cancers. The company’s tests are supported by extensive clinical evidence with over seven million patients tested worldwide as of mid–2024. They continue to expand their menu of distributed IVDs globally while maintaining a strong presence in centralized CLIA lab-based testing in the US. Recent expansions include making the Decipher Prostate Test available to metastatic prostate patients.